Promoter hypermethylation of FANCF:: Disruption of Fanconi Anemia-BRCA pathway in cervical cancer

被引:152
作者
Narayan, G
Arias-Pulido, H
Nandula, SV
Basso, K
Sugirtharaj, DD
Vargas, H
Mansukhani, M
Villella, J
Meyer, L
Schneider, A
Gissmann, L
Dürst, M
Pothuri, B
Murty, VVVS
机构
[1] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Gynecol Oncol, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA
[4] Univ New Mexico, Dept Mol Genet, Albuquerque, NM 87131 USA
[5] Univ New Mexico, Dept Microbiol, Albuquerque, NM 87131 USA
[6] Natl Canc Inst, Dept Tumor Mol Biol, Bogota, Colombia
[7] Univ Jena, Dept Obstet & Gynecol, D-6900 Jena, Germany
[8] Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-6900 Heidelberg, Germany
关键词
D O I
10.1158/0008-5472.CAN-04-0245
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with advanced stage invasive cervical cancer (CC) exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols. In our efforts to understand the molecular genetic basis of CC, we examined the role of Fanconi Anemia (FA)-BRCA pathway. Here, we show that FANCF gene is disrupted by either promoter hypermethylation and/or deregulated gene expression in a majority of CC. Inhibition of DNA methylation and histone deacetylases induces FANCF gene re-expression in CC cell lines. FANCF-deregulated CC cell lines also exhibit a chromosomal hypersensitivity phenotype after exposure to an alkylating agent, a characteristic of FA patients. We also show the involvement of BRCA1 gene by promoter hypertmethylation or down-regulated expression in a small subset of CC patients. Thus, we have found inactivation of genes in the FA-BRCA pathway by epigenetic alterations in a high proportion of CC patients, suggesting a major role for this pathway in the development of cervical cancer. Thus, these results have important implications in understanding the molecular basis of CC tumorigenesis and clinical management in designing targeted experimental therapeutic protocols.
引用
收藏
页码:2994 / 2997
页数:4
相关论文
共 20 条
[1]   Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene [J].
Bachman, KE ;
Park, BH ;
Rhee, I ;
Rajagopalan, H ;
Herman, JG ;
Baylin, SB ;
Kinzler, KW ;
Vogelstein, B .
CANCER CELL, 2003, 3 (01) :89-95
[2]   SPLASH: structural pattern localization analysis by sequential histograms [J].
Califano, A .
BIOINFORMATICS, 2000, 16 (04) :341-357
[3]  
CALIFANO A, 2000, ISMB, V8, P75
[4]   The Fanconi anaemia BRCA pathway [J].
D'Andrea, AD ;
Grompe, M .
NATURE REVIEWS CANCER, 2003, 3 (01) :23-34
[5]  
FAHMER JA, 2002, CANCER RES, V62, P7213
[6]   Comprehensive molecular cytogenetic characterization of cervical cancer cell lines [J].
Harris, CP ;
Lu, XY ;
Narayan, G ;
Singh, B ;
Murty, VVVS ;
Rao, PH .
GENES CHROMOSOMES & CANCER, 2003, 36 (03) :233-241
[7]   The emerging genetic and molecular basis of Fanconi anaemia [J].
Joenje, H ;
Patel, KJ .
NATURE REVIEWS GENETICS, 2001, 2 (06) :446-457
[8]   Cancer epigenetics comes of age [J].
Jones, PA ;
Laird, PW .
NATURE GENETICS, 1999, 21 (02) :163-167
[9]   The fundamental role of epigenetic events in cancer [J].
Jones, PA ;
Baylin, SB .
NATURE REVIEWS GENETICS, 2002, 3 (06) :415-428
[10]   A 20-year perspective on the International Fanconi Anemia Registry (IFAR) [J].
Kutler, DI ;
Singh, B ;
Satagopan, J ;
Batish, SD ;
Berwick, M ;
Giampietro, PF ;
Hanenberg, H ;
Auerbach, AD .
BLOOD, 2003, 101 (04) :1249-1256